Skip to main content
Caplight Logo









Op2Lysis

Op2Lysis

Private
Boulogne-BillancourtHealthcare & Life Scienceshttps://www.op2lysis.com/

Last Round

Series A

Nov 4, 2024

Total Funding Raised

$12.55M

Company Overview

Op2Lysis is a biotechnology company that develops innovative medicines for the treatment of hemorrhagic stroke using its proprietary NANOp2Lysis® technology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical Devices

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

thrombolytic therapyhemorrhagic strokedrug delivery platformintracerebral hematomabiotech startupnanotechnologyneurovascular diseaseminimally invasive surgerydrug developmentstroke treatmentpharma licensingnanomedicinepreclinical biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Op2Lysis Comparables

Compare Op2Lysis with similar companies based on industry and business-model similarity.

Op2Lysis comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Bioxodes
86%
Lys Therapeutics
77%
Basking Biosciences
75%

Op2Lysis Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ANov 4, 2024
GrantJul 7, 2023
AcceleratorOct 1, 2021
Early FundingDec 1, 2020
SeedApr 1, 2018

Key People

Founding team and executive leadership

Jérôme Parcq

Co-founder General Manager Chief Strategic and Scientific Officer

Founding Team

Christophe Gaudin

CEO, Cofounder

Founding Team

Op2Lysis Investors

Notable investors and investment history

Op2Lysis investors
InvestorRounds
European Innovation Council FundAccelerator
NoshaqEarly Funding
WiSeedSeed
BpifranceGrant
BeAngelsEarly Funding

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 4, 2024

    $29.16M Series A round completed.

  • Jul 7, 2023

    $1.65M grant received from Bpifrance.

Op2Lysis Filings

Explore SEC and related filing metadata, where available.

Op2Lysis filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Op2Lysis's valuation, stock price, and market status.

Is Op2Lysis a public or private company?

Op2Lysis is a private company.

What is the current stock price of Op2Lysis?

Op2Lysis is a private company with no public stock price. Caplight tracks Op2Lysis's secondary market activity and provides MarketPrice™ estimates to Caplight users.

How much is Op2Lysis worth (valuation)?

Valuation information for Op2Lysis is not publicly available.

Can I buy Op2Lysis stock?

Op2Lysis shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Op2Lysis's last funding round?

Op2Lysis's most recent funding round was Series A on November 4, 2024.

Who are the main investors in Op2Lysis?

Key investors in Op2Lysis include European Innovation Council Fund, Noshaq, WiSeed, Bpifrance, BeAngels.

Will Op2Lysis IPO soon?

No public IPO plans have been announced for Op2Lysis.

How can I track Op2Lysis secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Op2Lysis's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBoulogne-Billancourt
Employee Range4
Year Founded2016
Last FundingNov 4, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?